- In April 2023, Evonik Industries AG, a global specialty chemicals leader, expanded its production capacity for RESOMER, a biodegradable polymer used in medical devices and drug delivery systems. This strategic move supports growing global demand for bioresorbable materials in orthopedic, cardiovascular, and oncology applications. The expansion enhances Evonik's capability to supply high-quality biomedical materials that meet stringent regulatory standards, reinforcing its leadership in the advanced biomaterials segment
- In March 2023, DSM Biomedical, a subsidiary of DSM-Firmenich, partnered with the University of Maastricht to advance collagen-based regenerative technologies for soft tissue repair. The collaboration focuses on developing next-generation materials that promote natural healing and improve patient outcomes in orthopedic and dental surgeries. This move highlights DSM's ongoing commitment to innovation and collaboration in regenerative medicine
- In March 2023, BASF SE launched Steronyl, a new line of sterilizable engineering plastics tailored for medical device applications, including surgical instruments and implantable components. The material offers excellent biocompatibility, high strength, and thermal stability, making it ideal for healthcare manufacturers seeking reliable biomedical solutions. This product launch reinforces BASF’s role in supplying specialized polymers for advanced medical use
- In February 2023, Corbion N.V., a leader in lactic acid-based biomaterials, announced the development of a new PLA-PGA composite for absorbable sutures and implants. Designed to meet growing clinical demands for precision and performance, the material offers tailored degradation rates and mechanical properties. This innovation aligns with Corbion’s mission to create sustainable, patient-focused solutions in biomedical applications
- In January 2023, Collagen Matrix, Inc. received FDA 510(k) clearance for its OsteoMatrix+ Bone Graft Matrix, designed to support bone regeneration in orthopedic and dental procedures. The product combines mineralized collagen with a proprietary polymer matrix, offering improved handling and biological performance. This regulatory milestone emphasizes Collagen Matrix’s dedication to developing advanced, clinically validated materials for regenerative medicine
